icon

With another five percent price increase in the bags on a day that saw the second highest trading volume of the new year, it could be time to start considering GelTech Solutions (GLTC.OB) for a continued move towards a dollar - if not higher - as the company looks to revolutionize firefighting as we know it...

Read more

For a few years now Titan Pharmaceuticals (TTNP.OB) has been one of those companies whose share price has continuously provided many opportune times to play a quick trade, after having traded for just a couple of pennies back in 2009 before riding high to two dollars at some points, and then slipping back to a buck at others.

Decent gains could be had by all ...

Read more

Positive updates from the Ampio Pharmaceuticals' (AMPE) pipeline sparked a run to nearly ten dollars last year, before the share price started trickling back down to earth and hit lows of under four bucks in December following a round of negative articles posted on various Internet media outlets that questioned the company's practices, procedures and accuracy of reporting.

Some looked at the late-year slide as a buying opportunity, given the fact that there were still multiple potential catalysts pending on the pipeline front...

Read more

Fueled by news that the ongoing Phase II trial for ICT-107 in the treatment of glioblastoma is enrolling patients ahead of schedule, shares of Immunocellular Therapeuticas (IMUC.OB) have already become a documented rebound story early this year after temporarily dropping to below a buck earlier this month after the announcement of a financing deal.

IMUC has long been a stock to watch in the cancer immunotherapy sector, given the impressive Phase I trial results for ICT-107 that had 100% of the 16 patients treated still alive after one year, and 80% after two, but it's the technology behind this company's products that could very well usher in the next generation of cancer immunotherapy treatments...

Read more

At the conclusion of each week, VFC's Stock House examines the stocks and stories that made news through various sectors during previous trading week, but may also make headlines or influence trends during the upcoming week as well.

This week - in honor of the upcoming Super Bowl that'll see the Giants repeat their previous big game success against the Pats - we'll focus on some of the high runners from last week, which also might be ready to make some noise during the upcoming trading week as well.

Like money placed on the Giants in San Fransisco, money placed on the following stocks could also be a good move, judging by recent events and price action...

Read more

It could be shaping up to become a big year for GelTech Solutions (OTCBB: GLTC).  Holding a revolutionary technology with global implications, this company could go to the next level in quick time.

As introduced to readers of VFC's Stock House late last year, and the fuel behind what could become a boom in growth for the company, GelTech's 'FireIce' is a revolutionary dry powder that, when combined with water, has proven to be a far more effective tool for extinguishing fires than water alone...

Read more

While Dendreon (DNDN) made history by being the first company to receive an FDA approval for an immunotherapeutic cancer treatment with Provenge, Immunocellular Therapeutics (IMUC.OB) looks to usher in the next generation of such treatments.  Immunocellular may even be able to do the technology behind Provenge one better, as the process behind administering IMUC's treatment holds some logistical advantages over Dendreon's...

Read more

With all the big runners that have already left their mark during the opening weeks of 2012, Mannkind Corporation (MNKD) has remained relatively silent.

That could all change in a hurry, however, as very heavy short interest and a fair amount of insider ownership have many looking at this one as a potential short squeeze candidate.  We'll keep in mind, though, that it'll take relevant news to turn what has been slow and steady short covering into a big-money squeeze.  The normal, "maybe this, maybe that" probably won't cut it...

Read more

It's been a little more than two years now since CVM made some real noise on the market, but recent events may be creating another perfect storm of news and attention that could spark new life into this potential big game play...

Whether it was related to trading under the radar or due to a general lack of investor interest since the Multikine Phase III trial was still in its earlier stages, shares of Cel-Sci Corp. (CVM) spent the better part of last year stuck in a rut that did little to inspire confidence or enthusiasm for what might be in store...

Read more

At the conclusion of each week, VFC's Stock House examines the stocks and stories that made news through various sectors during previous trading week, but may also make headlines or influence trends during the upcoming week as well.

This week the focus is on the biotechnology and pharmaceutical sectors, where many stocks have already experienced significant runs over the past few weeks, while others have not - but might be primed to do so.  A special emphasis is placed on the cancer immunotherapy sector, where Dendreon's revival has attracted new interest to the sector as a whole.

Here's just a few of the stories to watch, as if the Giants laying it down in Lambeau wasn't enough...

Read more

BDSI: A Pipeline Rejuvenated

Posted by Posted by VFC on Jan 13, 2012

The resolution of the REMS issues for Onsolis, BioDelivery Science's (BDSI) treatment for breakthrough pain in cancer patients, and a money new partnership with Endo Pharmaceuticals (ENDP) to bring BEMA Buprenorphine to market had BDSI trading higher by over 100% earlier this month, but the stock received another huge boost this week when a two-million-share trading day on Thursday launched BDSI right through two dollars again for a 20% gain on the day...

Read more

Our notes on Thursday highlighted the 2012 potential of Accentia Biopharmaceuticals (ABPI) and its majority-owned subsidiary Biovest International (BVTI) based on the progression of BVTI's late stage immunotherapeutic treatment for non-Hodgkin's lymphoma, BiovaxID. Non-Hodgkin's lymphoma is an incurable form of blood cancer and it's expected that Biovest will officially file for approval with the FDA later this year.

Another press release hit the wires on Thursday...

Read more

Biovest International (BVTI.pk) and Accentia Biopharmaceuticals (ABPI.pk) have both been enjoying increased exposure, even if their respective share prices have not shown it yet.  Biovest, a majority-owned subsidiary of Accentia, has been developing BiovaxID for the treatment of non-Hodgkin's lymphoma, an incurable form of blood cancer.

It's been a rough going for both companies over ...

Read more

Earlier this week we discussed the rising price trends of both Dendreon (DNDN) and Advanced Cell Technology (OTCBB:  ACTC), as both stocks made significant gains during the opening weeks of 2012.

Dendreon, out to prove that its immunotherapeutic treatment for prostate cancer, Provenge, was no fluke, soared to over fourteen dollars this week, after closing out 2011 at under eight.

Advanced Cell, on the other hand, hit highs of right around seventeen cents on heavy volume, before...

Read more

Questions remain for many shareholders who cannot fathom why shares of Ctyosorbents (OTCBB:  CTSO) remain trading for under twenty cents after a milestone year that saw the company realize its first regulatory approval, while making nice inroads into the European market with CytoSorb as a treatment for severe sepsis and other indications where high cytokines are present.

There's been little price action since the approval had the stock take a trip to the north side of forty cents last year, although there have been spurts of volume that appeared at various points during the ongoing CytoSorb road show...

Read more

After briefly spiking during last year's closing months on a positive sales update for Benlysta and takeover chatter from across the pond, the heavily shorted shares of Human Genome Sciences (HGSI) dropped to below seven dollars at one point, before closing 2011 at just over that mark. 

The tide has turned during the opening weeks of the new year, however, and heavy volume accompanied a near-20% price spike on Wednesday, potentially indicating a large round of short covering after representatives of Human Genome made positive comments relating to the overall 2011 sales of Benlysta, a trend expected to continue into 2012...

Read more

As noted earlier this week, GelTech Solutions (OTCBB: GLTC) started making some noise late last year when the company's novel, water-enhancing firefighting product, FireIce, received key regulatory approvals to potentially be used in large-scale firefighting efforts globally. 

The company also launched a new website in preparation for a year that could turn into one of significant growth as brand awareness and increased distribution channels for FireIce turns into sales revenue...

Read more

NovaBay Pharmaceuticals (NBY) spent the better part of late 2011 gaining increased attention for its proprietary technology that might offer a groundbreaking solution to the dilemma of antibiotic resistance.  Resistance to common antibiotics has become a huge concern in the medical industry and has very significant monetary implications on the exploding costs associated with health care.  Owning a solution that could solve these problems - since NBY's "Aganocide" technology mimics the body's own defense systems against infection by essentially acting as white blood cells, thereby eliminating the risk of a patient developing resistance -  Novabay stands to benefit greatly, should the technology make it to market in the various indications for which it is being tested...

Read more

DNDN: The Surge Continues

Posted by Posted by VFC on Jan 10, 2012

After opening the year on the highlight list of hot-running stocks, the high-volumed surge of Dendreon (DNDN) continued again on Monday with another dollar price increase and a close of $13.31.  That all came to fruition in just five trading sessions after DNDN closed 2011 at $7.60.

The rapid price action followed an announcement by the company that Provenge sales for the fourth quarter beat expectations and were 25% higher than the previous quarter.  It's fair to note, however, that the exceeded expectations were actually revised from the company's original projections, which had full year 2011 sales rolling in to the tune of between $350-500 million...

Read more

Advanced Cell Technology (OTCBB:  ACTC) opened 2011 as a stock on the rise when monumental volume pushed shares from the area of six cents to the mid twenties within just weeks after the FDA granted an historic authorization to allow the company to commence a trial based on its embryonic stem cell-based retinal pigment epithelium (RPE) program to treat severe vision loss.

At the time, it was only the second such authorization granted by the FDA concerning an embryonic stem cell based therapy, the first having been granted to Geron (GERN), who has since put its stem cell program on hold...

Read more

The dog days might be done for Dendreon (DNDN).

Dendreon's share price collapsed last summer when it became apparent that sales numbers were lagging for Provenge - Dendreon's milestone immunotherapeutic treatment for prostate cancer that made history when it was approved by the FDA in May of 2010 -  and many all but wrote the company off as new competition was able to gain a foothold in the market while massive restructuring got underway at Dendreon HQ.

The tide may have turned, however, both in terms of Provenge sales numbers and in a trend reversal for the DNDN share price.  As noted ...

Read more

With nearly five million shares traded and a 120% price increase on Friday, BioDelivery Sciences (BDSI) was unsurprsingly one of the most talked about stocks heading into the weekend after the small company whose stock has a daily trading average of under 300,000 signed a worldwide licensing and development agreement with Endo Pharmaceuticals (ENDP) to bring BEMA Buprenorphine to market. 

BEMA Bup, as its known for short, failed to meet the primary endpoint of a Phase III trial completed earlier this year, although company CEO Dr. Mark Sirgo said at the time that some data from the trial was compelling enough to warrant additional studies...

Read more

At the conclusion of each week, VFC's Stock House examines the stocks and stories that made news through various sectors during the week and which could also make headlines or influence trading trends during the upcoming trading week as well.

This week, with a full week of 2012 trading now in the bag, we'll take a look at a few stocks that have already made some noise and are possibly setting up for a strong year ahead...

BDSI: A few months ago BioDelivery Sciences (BDSI) announced that the primary endpoint of its Phase III trial for BEMA Buprenorphine was missed, although company CEO Mark Sirgo also implied that some results were encouraging enough that additional trials were warranted, should the necessary financing or partnership be put into place.

At the time, shares of BDSI followed a trend that saw the stock sink to below a dollar on the news...

Read more